Literature DB >> 956401

Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man.

P Felig, J Wahren, R Hendler.   

Abstract

To evaluate the effects of physiologic hyperglucagonemia on splanchnic glucose output, glucagon was infused in a dose of 3 ng/kg per min to healthy subjects in the basal state and after splanchnic glucose output had been inhibited by an infusion of glucose (2 mg/kg per min). In the basal state, infusion of glucagon causing a 309 +/- 25 pg/ml rise in plasma concentration was accompanied by a rapid increase in splanchnic glucose output to values two to three times basal by 7-15 min. The rise in arterial blood glucose (0.5-1.5 mM) correlated directly with the increment in splanchnic glucose output. Despite continued glucagon infusion, and in the face of stable insulin levels, splanchnic glucose output declined after 22 min, returning to basal levels by 30-45 min. In the subjects initially receiving the glucose infusion, arterial insulin concentration rose by 5-12 muU/ml, while splanchnic glucose output fell by 85-100%. Infusion of glucagon causing an increment in plasma glucagon concentration of 272 +/- 30 pg/ml reversed the inhibition in splanchnic glucose production within 5 min. Splanchnic glucose output reached a peak increment 60% above basal levels at 10 min, and subsequently declined to levels 20-25% below basal at 30-45 min. These findings provide direct evidence that physiologic increments in plasma glucagon stimulate splanchnic glucose output in the basal state and reverse insulin-mediated inhibition of splanchnic glucose production in normal man. The transient nature of the stimulatory effect of glucagon on splanchnic glucose output suggests the rapid development of inhibition or reversal of glucagon action. This inhibition does not appear to depend on increased insulin secretio.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956401      PMCID: PMC333235          DOI: 10.1172/JCI108523

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Use of glucose oxidase, peroxidase, and O-dianisidine in determination of blood and urinary glucose.

Authors:  A S HUGGETT; D A NIXON
Journal:  Lancet       Date:  1957-08-24       Impact factor: 79.321

2.  Effect of protein ingestion on splanchnic and leg metabolism in normal man and in patients with diabetes mellitus.

Authors:  J Wahren; P Felig; L Hagenfeldt
Journal:  J Clin Invest       Date:  1976-04       Impact factor: 14.808

3.  Separation of antibody-bound and unbound peptide hormones labelled with iodine-131 by talcum powder and precipitated silica.

Authors:  G Rosselin; R Assan; R S Yalow; S A Berson
Journal:  Nature       Date:  1966-10-22       Impact factor: 49.962

4.  Insulin control of glucose metabolism in man: a new kinetic analysis.

Authors:  P A Insel; J E Liljenquist; J D Tobin; R S Sherwin; P Watkins; R Andres; M Berman
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

5.  Influence of uremia and hemodialysis on the turnover and metabolic effects of glucagon.

Authors:  R S Sherwin; C Bastl; F O Finkelstein; M Fisher; H Black; R Hendler; P Felig
Journal:  J Clin Invest       Date:  1976-03       Impact factor: 14.808

6.  Is glucagon important in stable insulin-dependent diabetics?

Authors:  A J Barnes; A Bloom; M F Crowley; J W Tuttlebee; S R Bloom; K G Alberti; P Smythe; D Turnell
Journal:  Lancet       Date:  1975-10-18       Impact factor: 79.321

7.  Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man.

Authors:  J K Wise; R Hendler; P Felig
Journal:  J Clin Invest       Date:  1973-11       Impact factor: 14.808

8.  Effect of glucagon on net splanchnic cyclic AMP production in normal and diabetic men.

Authors:  J E Liljenquist; J D Bomboy; S B Lewis; B C Sinclair-Smith; P W Felts; W W Lacy; O B Crofford; G W Liddle
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

9.  Substrate turnover during prolonged exercise in man. Splanchnic and leg metabolism of glucose, free fatty acids, and amino acids.

Authors:  G Ahlborg; P Felig; L Hagenfeldt; R Hendler; J Wahren
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

10.  Influence of endogenous insulin secretion on splanchnic glucose and amino acid metabolism in man.

Authors:  P Felig; J Wahren
Journal:  J Clin Invest       Date:  1971-08       Impact factor: 14.808

View more
  20 in total

1.  Cyclic AMP metabolism and adenylate cyclase concentration in patients with advanced hepatic cirrhosis.

Authors:  A Francavilla; A F Jones; T E Starzl
Journal:  Gastroenterology       Date:  1978-12       Impact factor: 22.682

Review 2.  Glucagon and lipid signaling in the hypothalamus.

Authors:  Mary P LaPierre; Mona A Abraham; Beatrice M Filippi; Jessica T Y Yue; Tony K T Lam
Journal:  Mamm Genome       Date:  2014-04-10       Impact factor: 2.957

Review 3.  Glucagon action in the brain.

Authors:  Mona A Abraham; Tony K T Lam
Journal:  Diabetologia       Date:  2016-04-26       Impact factor: 10.122

Review 4.  Glucagon and diabetes: a reappraisal.

Authors:  P J Lefebvre; A S Luyckx
Journal:  Diabetologia       Date:  1979-06       Impact factor: 10.122

5.  Metabolic and hormonal effects of muscular exercise in juvenile type diabetics.

Authors:  M Berger; P Berchtold; H J Cüppers; H Drost; H K Kley; W A Müller; W Wiegelmann; H Zimmerman-Telschow; F A Gries; H L Krüskemper; H Zimmermann
Journal:  Diabetologia       Date:  1977-08       Impact factor: 10.122

6.  The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans.

Authors:  Y M Fong; M A Marano; L L Moldawer; H Wei; S E Calvano; J S Kenney; A C Allison; A Cerami; G T Shires; S F Lowry
Journal:  J Clin Invest       Date:  1990-06       Impact factor: 14.808

7.  Effect of glucagon on glucose production during insulin deficiency in the dog.

Authors:  A D Cherrington; W W Lacy; J L Chiasson
Journal:  J Clin Invest       Date:  1978-09       Impact factor: 14.808

8.  Synergistic interactions of physiologic increments of glucagon, epinephrine, and cortisol in the dog: a model for stress-induced hyperglycemia.

Authors:  N Eigler; L Saccà; R S Sherwin
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

9.  Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.

Authors:  R Rizza; C Verdonk; J Miles; F J Service; J Gerich
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

10.  Hypothalamic glucagon signaling inhibits hepatic glucose production.

Authors:  Patricia I Mighiu; Jessica T Y Yue; Beatrice M Filippi; Mona A Abraham; Madhu Chari; Carol K L Lam; Clair S Yang; Nikita R Christian; Maureen J Charron; Tony K T Lam
Journal:  Nat Med       Date:  2013-05-19       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.